What is he best known for?
The fields of study he is best known for:
Ross L. Levine mainly investigates Cancer research, Immunology, Myeloid, Mutation and Myelofibrosis.
His Cancer research research includes elements of Myeloproliferative neoplasm, Somatic cell, Myeloproliferative Disorders, Erythropoietin receptor and Leukemia.
His research integrates issues of Myeloid leukemia and IDH1 in his study of Leukemia.
In his work, Oncology is strongly intertwined with Internal medicine, which is a subfield of Immunology.
His Myeloid research integrates issues from IDH2, Haematopoiesis and Bone marrow.
His research investigates the connection between Myelofibrosis and topics such as Polycythemia vera that intersect with problems in Janus kinase 2 and Extramedullary hematopoiesis.
His most cited work include:
- The landscape of somatic copy-number alteration across human cancers (2544 citations)
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2498 citations)
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2498 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Cancer research, Myeloid leukemia, Immunology, Internal medicine and Myeloid.
His Cancer research study combines topics from a wide range of disciplines, such as Haematopoiesis, Signal transduction, Janus kinase 2, Mutation and Leukemia.
While the research belongs to areas of Haematopoiesis, he spends his time largely on the problem of Molecular biology, intersecting his research to questions surrounding DNA methylation.
His Myeloid leukemia study combines topics in areas such as IDH2 and Epigenetics.
Immunology is represented through his Myelofibrosis, Pathogenesis and Myelodysplastic syndromes research.
His studies deal with areas such as Essential thrombocythemia, Myeloproliferative Disorders and Thrombopoietin receptor as well as Myelofibrosis.
He most often published in these fields:
- Cancer research (47.18%)
- Myeloid leukemia (25.35%)
- Immunology (24.79%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (47.18%)
- Internal medicine (21.83%)
- Leukemia (21.41%)
In recent papers he was focusing on the following fields of study:
Ross L. Levine mostly deals with Cancer research, Internal medicine, Leukemia, Myeloid leukemia and Oncology.
His study in Cancer research focuses on Myeloid in particular.
His Leukemia research is multidisciplinary, incorporating perspectives in Kinase and Somatic evolution in cancer.
His biological study deals with issues like IDH2, which deal with fields such as Enasidenib.
The concepts of his Oncology study are interwoven with issues in Myelofibrosis, Ruxolitinib, Decitabine and Transplantation.
His biological study spans a wide range of topics, including Essential thrombocythemia and Polycythemia vera.
Between 2017 and 2021, his most popular works were:
- Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. (181 citations)
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. (132 citations)
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. (114 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Ross L. Levine focuses on Cancer research, Leukemia, Myeloid leukemia, Myeloid and Haematopoiesis.
Ross L. Levine has included themes like Cancer, Myeloproliferative neoplasm, Mutation and Progenitor cell, Stem cell in his Cancer research study.
His work deals with themes such as Survival rate, Kinase, Gastroenterology and Somatic evolution in cancer, which intersect with Leukemia.
His Myeloid leukemia research is multidisciplinary, relying on both Epigenetic therapy, Epigenetics and NPM1.
His Myeloid research incorporates elements of Enasidenib and Oncology.
Much of his study explores Myelofibrosis relationship to Essential thrombocythemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
